Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ANPEP | P15144 | 2/20 | 0.51 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25229867 | 1.00 | SLC7A5 (0.61) | SLC7A5TAAR1SLC6A2ANPEPENPEP | |
| SCHEMBL28064695 | 0.85 | ANPEP (0.51) | SLC7A5ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL27999577 | 0.85 | ANPEP (0.51) | SLC7A5ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL28064620 | 0.85 | ANPEP (0.51) | SLC7A5ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL20707602 | 0.85 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ANPEPENPEP | |
| SCHEMBL28064621 | 0.85 | ANPEP (0.51) | SLC7A5ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL288929 | 0.85 | ANPEP (0.51) | SLC7A5ANPEPENPEPS1PR2S1PR1 | |
| SCHEMBL287736 | 0.84 | EPHX1 (0.64) | SLC7A5ANPEPENPEP | |
| SCHEMBL197907 | 0.84 | EPHX1 (0.64) | SLC7A5ANPEPENPEP | |
| SCHEMBL123055 | 0.84 | EPHX1 (0.64) | SLC7A5ANPEPENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115698053-A | Long-acting casein Peptide (PYY) analogs and methods of use | I2O治疗公司 | 2023-02-03 | — | — | CN | claimed |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2018-07-10 | — | — | US | claimed |
| EP-2836485-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2018-01-10 | — | — | EP | claimed |
| EP-2499148-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2017-01-18 | — | — | EP | claimed |
| US-9512139-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | POLYPHOR AG (CH) | 2016-12-06 | — | — | US | claimed |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2015-02-19 | — | — | US | claimed |
| EP-2836485-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2015-02-18 | — | — | EP | claimed |
| EP-2462147-B1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2014-11-12 | — | — | EP | claimed |
| WO-2013139697-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2013-09-26 | — | — | WO | claimed |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2012-10-25 | — | — | US | claimed |
| EP-2499148-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | Polyphor Ag (CH) | 2012-09-19 | — | — | EP | claimed |
| WO-2011014973-A2 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | POLYPHOR AG (CH) | 2011-02-10 | — | — | WO | claimed |
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | GENEFRONTIER CORPORATION (JP) | 2026-03-03 | — | — | US | disclosed |
| CN-104984319-B | TFPI inhibitors and methods of use | 武田药品工业株式会社 | 2025-05-09 | — | — | CN | disclosed |
| CN-118613492-A | TFPI binding polypeptides and uses thereof | 西湖大学 | 2024-09-06 | — | — | CN | disclosed |
| US-12065485-B2 | Treatment of staphylococcal disorders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-20 | — | — | US | disclosed |
| US-20070042461-A1 | Compositions for protein biosynthetic machinery; orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases and orthogonal pairs of lysyl-tRNAs/synthetases which incorporate homoglutamines into proteins are provided in response to four base codon; biosynthesis enzyme; therapeutic use | THE SCRIPPS RESEARCH INSTITUTE | 2007-02-22 | — | — | US | disclosed |
| US-20070042461-A1 | Compositions for protein biosynthetic machinery; orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases and orthogonal pairs of lysyl-tRNAs/synthetases which incorporate homoglutamines into proteins are provided in response to four base codon; biosynthesis enzyme; therapeutic use | THE SCRIPPS RESEARCH INSTITUTE | 2007-02-22 | — | — | US | disclosed |
| US-20070020634-A1 | Composition of orthogonal glutamyl-trna and aminoacyl-trna synthetase pairs and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-01-25 | — | — | US | disclosed |
| US-20070020634-A1 | Composition of orthogonal glutamyl-trna and aminoacyl-trna synthetase pairs and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12565517-B2 | Cyclic peptide having CTLA-4 inhibitory activity and use thereof | CXCL10, MLX, MICA | SLC7A5 1811/4885TAAR1 3475/4885SLC6A2 3691/4885 |
| US-20070020634-A1 | Composition of orthogonal glutamyl-trna and aminoacyl-trna synthetase pairs and uses thereof | AARS1, GARS1, EPRS1 | SLC7A5 827/4885TAAR1 4451/4885SLC6A2 4206/4885 |
| US-10017481-B2 | Conformationally constrained, fully synthetic macrocyclic compounds | CTSE, CTSB, CTSS | SLC7A5 1084/4885TAAR1 151/4885SLC6A2 4431/4885 |
| US-20120270881-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | KCNB1, KCNAB1, KCNMB1 | SLC7A5 1849/4885TAAR1 1686/4885SLC6A2 1551/4885 |
| US-20150051183-A1 | CONFORMATIONALLY CONSTRAINED, FULLY SYNTHETIC MACROCYCLIC COMPOUNDS | CTSE, CTSB, CTSS | SLC7A5 1084/4885TAAR1 151/4885SLC6A2 4431/4885 |
| US-20070042461-A1 | Compositions for protein biosynthetic machinery; orthogonal lysyl-tRNAs, orthogonal lysyl-aminoacyl-tRNA synthetases and orthogonal pairs of lysyl-tRNAs/synthetases which incorporate homoglutamines into proteins are provided in response to four base codon; biosynthesis enzyme; therapeutic use | AARS1, GARS1, OSGEP | SLC7A5 529/4885TAAR1 4155/4885SLC6A2 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.